Prostate Cancer Industry, March 2015 Market Reports from Top Publishers

You might be interested in: drug, cancer, medical equipment, cancer drug, nucleic acid testing, therapeutics, melanoma, hormone, plc, ultrasound, cancer therapeutics, lymphoma, magnetic resonance imaging, leukemia, oncology.


 
1-10 of about 200 reports for Prostate Cancer

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive ...

Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed ...

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across ...

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides ...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, ‘Hormone Refractory (Castration Resistant, Androgen-Independent) ...

Metastatic Prostate Cancer - Pipeline Review, H1 2015

Metastatic Prostate Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

Metastatic Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, ‘Metastatic Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Prostate Cancer's ...

Prostate Cancer Drug Pathway Analyzer 2015

Prostate Cancer Drug Pathway Analyzer 2015

  • $ 2 249
  • Industry report
  • January 2015
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 413 targeted molecular therapies known to affect more than 249 specific intracellular signaling pathways ...

Bavarian Nordic A/S (Symbol:BAVA) SWOT Analysis, Strategy, Revenues and Profits

Bavarian Nordic A/S (Symbol:BAVA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Bio-Path Holdings, Inc. (Symbol:BPTH) SWOT Analysis, Strategy, Revenues and Profits

Bio-Path Holdings, Inc. (Symbol:BPTH) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

GeneNews Limited (Symbol:GEN) SWOT Analysis, Strategy, Revenues and Profits

GeneNews Limited (Symbol:GEN) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

About 2 200 reports for Prostate Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK Forecast

  • January 2014
    28 pages
  • Prostate Cancer  

    Cancer  

  • United Kingdom  

View report >

4 Companies for Prostate Cancer

Read our Company Profiles

Johnson and Johnson

United States

Novartis Inc.

Switzerland

AstraZeneca PLC

United Kingdom

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.